NCT02499497View on ClinicalTrials.gov

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Prostate Cancer
Interventions
DRUG

LY2452473

LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.

DRUG

Placebo

The participants will receive pills containing no active drug.

Trial Locations (4)

21231

John Hopkins Medical Center, Baltimore

32611

University of Florida, Gainesville

02115

Beth Israel Deaconess Medical Center (Referring site only), Boston

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Nursing Research (NINR)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT02499497 - A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer | Biotech Hunter | Biotech Hunter